Trained health care professionals (THCPs), including medical assistants, respiratory therapists, and nurses, with artificial intelligence (AI) assistance can achieve lung ultrasound (LUS) images with ...

The FDA approved two oncology regimens on Jan. 16.One is for a subset of patients with colorectal cancer and the other for ...

Scientists have found that a test to detect circulating tumor DNA can predict lung cancer outcome. Scientists from the Francis Crick Institute, UCL, UCLH and Personalis have found that a test to ...

Ultrasensitive ctDNA detection with NeXT Personal shows 81% sensitivity in early-stage lung adenocarcinoma, improving ...

Increase in sales of ProSense®, based on preliminary unaudited results, demonstrate growing adoption of ProSense® cryoablation for breast tumors.FDA decision on market authorization of ProSense® for ...

New research from the University of St Andrews School of Medicine has found that biomarker testing in individuals at risk of ...

The FDA granted priority review to a new drug application for sunvozertinib as an oral treatment for certain patients with ...

IceCure Medical’s next-generation cryoablation technology to receive European patent: Caesarea, Israel Monday, January 6, 2025, 13:00 Hrs [IST] IceCure Medical Ltd., a developer ...

Icecure Medical ( ) has issued an update. IceCure Medical has received an Intention to Grant Notice from the European Patent Office for its innovative cryogenic system connector t ...

XSense™ system's innovative cryogenic connector technology designed to improve safety and maintain the integrity of cryogen ...

XSensetm system's innovative cryogenic connector technology designed to improve safety and maintain the integrity of cryogen used in the cryoablation procedure CAESAREA, Israel, Jan. 3 ...

About IceCure Medical IceCure Medical (Nasdaq: ICCM) develops and markets advanced liquid-nitrogen-based cryoablation therapy ... bone and lung cancer. Its minimally invasive technology is a ...